Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02489617 · ClinicalTrials.gov registry record · NA
The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy
A NA study of Flat Epithelia Atypia and Intraductal Papilloma Without Atypia, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 246
- Enrollment target
- 18
- Study locations
NCT02489617: Completed NA study of Flat Epithelia Atypia and Intraductal Papilloma Without Atypia, sponsored by Dana-Farber Cancer Institute.
NCT02489617 is a NA study of Flat Epithelia Atypia and Intraductal Papilloma Without Atypia that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 246 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower). The trial reports 18 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02489617, a NA study of Flat Epithelia Atypia and Intraductal Papilloma Without Atypia, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 246 participants
- Enrollment target
- 18
- Study locations
Study Summary
This research study is studying a surgical intervention to rule out the presence of cancer in participants that have been diagnosed with flat epithelial atypia (FEA) or intraductal papilloma without atypia (IPWA) by core needle biopsy.
Conditions Studied
Interventions
- OTHER Pathologic evaluation of excised tissue
Study Locations (18)
Maryland
- MedStar Union Memorial Hospital - Baltimore
- MedStar Franklin Square Medical Center - Baltimore
- Johns Hopkins University - Baltimore
- Howard County General Hospital - Columbia
District of Columbia
- Georgetown University - Washington D.C.
- MedStar Washington Hospital Center - Washington D.C.
- Sibley Memorial Hospital - Washington D.C.
North Carolina
- University of North Carolina - Chapel Hill
- Duke University - Durham
- University of North Carolina - Hillsborough Campus - Hillsborough
New Jersey
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial SLoan Kettering Bergen - Montvale
New York
- Memorial Sloan Kettering Cancer Center - New York
- Montefiore Medical Center - The Bronx
Alabama
- University of Alabama at Birmingham - Birmingham
Indiana
- Indiana University - Indianapolis
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2015-09 |
| Est. Completion | 2025-06 |
| Phase | NA |
What the finished NCT02489617 record still lists
NCT02489617 is an interventional study that assigns participants to a tested intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Flat Epithelia Atypia appearing as the primary indexed condition, and to 1 intervention - of which Pathologic evaluation of excised tissue is the first listed.
NCT02489617 lists 18 locations in 9 states (Maryland, District of Columbia, North Carolina).
Frequently Asked Questions
What is clinical trial NCT02489617 about?
NCT02489617 is a clinical study titled "The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy". This research study is studying a surgical intervention to rule out the presence of cancer in participants that have been diagnosed with flat epithelial atypia (FEA) or intraductal papilloma without atypia (IPWA) by core needle biopsy.
What is the current status of trial NCT02489617?
This trial is currently completed. It is a NA study. The enrollment target is 246 participants. The study started on 2015-09. Estimated completion is 2025-06.
What conditions does trial NCT02489617 study?
This clinical trial studies the following conditions: Flat Epithelia Atypia, Intraductal Papilloma Without Atypia.
What interventions are being tested in trial NCT02489617?
The interventions under investigation include: Pathologic evaluation of excised tissue (OTHER).
Who is sponsoring clinical trial NCT02489617?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02489617 being conducted?
This trial has 18 study locations across Alabama, District of Columbia, Indiana, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02489617's enrollment target sits among peer trials
246 436th of 2000 higher than 1,565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04973605 · 246 participants · Phase 1
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- NCT06395168 · 246 participants · NA
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
- NCT07048769 · 246 participants · Phase 4
Paracervical Block for Pain Reduction in Saline Infusion Sonograms
- NCT07176650 · 246 participants · Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia